A California company recently began soliciting patients for a Food and Drug Administration Phase III new device investigation. The device is a miniature telescope that is inserted much like a lens implant is following cataract surgery.

Macular degeneration, both wet and dry versions, reduces the central acuity of the eye. This makes it difficult to see detailed objects such as print, signs, and facial characteristics of people. Severe macular degeneration may result in visual acuity levels of 20/400. 20/400 is represented by the big “E” on the eye chart. The company claims that central acuity may be improved several lines on the eye chart.

For additional information, go to the company’s web site at: www.visioncareinc.net. I am somewhat perturbed by the company’s misrepresentation of the improvement that would be obtained. This is demonstrated by the pictures below that were taken from the web site.

This series of pictures portrays a black central visionless area seen in the middle picture as being eliminated (third picture) with the telescope. The telescope will not eliminate the blindspot. It would magnify the areas around the black area making it somewhat easier to see.

It is difficult to predict if and when the implantable miniature telescope will receive FDA approval. It must first be demonstrated that it works and that it is safe. I will try to follow the data as it becomes available. If it looks promising, I may consider having some of my patients enter the study.